Skip to content

Study · Non-randomized trial · n = 14 · 1990

3 results

Preserving adult height potential in girls with idiopathic true precocious puberty.

Kreiter M, Burstein S, Rosenfield RL, Moll GW Jr, Cara JF, Yousefzadeh DK, Cuttler L, Levitsky LL

The Journal of pediatrics1 Sept 1990Cited by 44 (Europe PMC)

PMID2144020 (opens in a new tab)DOI10.1016/s0022-3476(05)81074-1 (opens in a new tab)PepBankPUB-02144020
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanNon-randomized trialMechanism

    In girls with precocious puberty and impaired height prognosis, nafarelin suppressed the pituitary-gonadal axis.

    In plain wordsIn girls with precocious puberty and impaired height prognosis, nafarelin suppressed reproductive hormone activity.

    Peptide
    Nafarelin
    Outcome
    DecreasePituitary-gonadal axis suppression
    Study

    n = 14

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In group 1, nafarelin therapy suppressed the pituitary-gonadal axis
    2 context sentences
    Summary · context
    We designed a prospective study of height potential in girls with idiopathic precocious puberty, comparing the presenting features of girls with and without evidence of reduced adult height potential.
    Summary · context
    The 14 girls with impaired adult height prognoses (group 1) were reexamined after treatment with a gonadotropin releasing hormone agonist, nafarelin.
  2. 02HumanNon-randomized trialEfficacy outcome

    In girls with impaired height prognosis, predicted height rose from 150.7 +/- 2.1 to 152.7 +/- 2.0 cm after 2 years of nafarelin. It also rose from 165.4 +/- 3.0 to 168.7 +/- 4.1 cm in girls with unimpaired prognosis followed without therapy.

    In plain wordsIn girls with impaired height prognosis, predicted height slightly rose over 2 years of nafarelin. It also rose in untreated girls with good prognosis.

    Peptide
    Nafarelin
    Outcome
    IncreasePredicted height
    Study

    n = 14

    Outcome group
    Linear growth · Musculoskeletal
    Studied dose
    Dose not stated · 2 yearsAs given in this study (human).

    Measurements

    Predicted height before
    150.7 cm
    group 1
    Predicted height after
    152.7 cm
    group 1
    P value
    < 0.05
    predicted height change

    Source sentences

    Summary
    2 years of treatment slightly improved predicted heights from 150.7 +/- 2.1 to 152.7 +/- 2.0 cm (p less than 0.05).
    3 context sentences
    Summary · context
    Height predictions also increased without therapy during the 2-year observation period in group 2, from 165.4 +/- 3.0 to 168.7 +/- 4.1 cm (p less than 0.05).
    Summary · context
    We designed a prospective study of height potential in girls with idiopathic precocious puberty, comparing the presenting features of girls with and without evidence of reduced adult height potential.
    Summary · context
    The 14 girls with impaired adult height prognoses (group 1) were reexamined after treatment with a gonadotropin releasing hormone agonist, nafarelin.
  3. 03HumanNon-randomized trialEfficacy outcome

    During the first 6 months of nafarelin therapy, girls with the youngest bone ages had a transient reduction in height potential.

    In plain wordsIn girls with the youngest bone ages, height potential temporarily decreased during the first 6 months of nafarelin therapy.

    Peptide
    Nafarelin
    Outcome
    DecreaseEarly height potential in youngest bone-age subgroup
    Study

    n: not reported in source

    Outcome group
    Linear growth · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    and although there was a transient reduction in height potential in girls with the youngest bone ages during the first 6 months of therapy
    2 context sentences
    Summary · context
    We designed a prospective study of height potential in girls with idiopathic precocious puberty, comparing the presenting features of girls with and without evidence of reduced adult height potential.
    Summary · context
    The 14 girls with impaired adult height prognoses (group 1) were reexamined after treatment with a gonadotropin releasing hormone agonist, nafarelin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.